FierceBiotechFierceBioResearcherFierceVaccinesFiercePharma   FierceHealthcare

ALSO NOTED: ImaRx prices IPO; Sepracor, Eisai sign deal for Lunesta; and much more...

> GSK has decided not to exercise its option to license Exelixis' non-small cell lung cancer drug XL647 for further development. Release

> ImaRX Therapeutics has priced its IPO at $5 per share. Release

> Chutes & Ladders: Silence Therapeutics has appointed Jeffery Scott Vick as Group CEO. Release

> Sepracor and Eisai have signed a deal development and commercialization of Sepracor's sleep drug Lunesta for the Japanese market. Release

And Finally... According to a Wake Forest University School of Medicine study, a class of drugs (which included Avandia and Actos) used to treat type 2 diabetes may double the risk of heart failure. Report

More stories about Sepracor   Wake Forest University School Of Medicine   Avandia   Actos   GlaxoSmithKline   Eisai   IPO   XL647   ImaRX Therapeutics  

Comments

Post new comment

The content of this field is kept private and will not be shown publicly.

More information about formatting options

What is 69 + 0?
To combat spam, please solve the math question above.